company background image
SRPT

Sarepta Therapeutics NasdaqGS:SRPT Stock Report

Last Price

US$122.89

Market Cap

US$10.8b

7D

-4.2%

1Y

71.7%

Updated

30 Jan, 2023

Data

Company Financials +

Sarepta Therapeutics, Inc.

NasdaqGS:SRPT Stock Report

Mkt Cap: US$10.8b

SRPT Stock Overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.

SRPT fundamental analysis
Snowflake Score
Valuation4/6
Future Growth6/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

New

Notes are coming soon

Sarepta Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sarepta Therapeutics
Historical stock prices
Current Share PriceUS$122.89
52 Week HighUS$134.08
52 Week LowUS$61.28
Beta1.01
1 Month Change-5.16%
3 Month Change7.72%
1 Year Change71.71%
3 Year Change6.56%
5 Year Change102.79%
Change since IPO215.10%

Recent News & Updates

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Jan 17
Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Recent updates

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Jan 17
Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Aug 22
Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

May 09
Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

Feb 07
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

A Look At The Intrinsic Value Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Dec 06
A Look At The Intrinsic Value Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Health Check: How Prudently Does Sarepta Therapeutics (NASDAQ:SRPT) Use Debt?

Nov 01
Health Check: How Prudently Does Sarepta Therapeutics (NASDAQ:SRPT) Use Debt?

Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?

Jul 19
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?

Most Shareholders Will Probably Agree With Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Compensation

May 27
Most Shareholders Will Probably Agree With Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Compensation

Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Are Analysts Optimistic?

Feb 23
Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Are Analysts Optimistic?

Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

Jan 26
Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

Imagine Holding Sarepta Therapeutics (NASDAQ:SRPT) Shares While The Price Zoomed 356% Higher

Dec 21
Imagine Holding Sarepta Therapeutics (NASDAQ:SRPT) Shares While The Price Zoomed 356% Higher

Should You Review Recent Insider Transactions At Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?

Nov 30
Should You Review Recent Insider Transactions At Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?

Shareholder Returns

SRPTUS BiotechsUS Market
7D-4.2%0.8%2.8%
1Y71.7%7.1%-9.2%

Return vs Industry: SRPT exceeded the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: SRPT exceeded the US Market which returned -9.2% over the past year.

Price Volatility

Is SRPT's price volatile compared to industry and market?
SRPT volatility
SRPT Average Weekly Movement5.1%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: SRPT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: SRPT's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1980840Doug Ingramhttps://www.sarepta.com

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.

Sarepta Therapeutics, Inc. Fundamentals Summary

How do Sarepta Therapeutics's earnings and revenue compare to its market cap?
SRPT fundamental statistics
Market CapUS$10.79b
Earnings (TTM)-US$716.22m
Revenue (TTM)US$876.05m

12.3x

P/S Ratio

-15.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SRPT income statement (TTM)
RevenueUS$876.05m
Cost of RevenueUS$917.93m
Gross Profit-US$41.88m
Other ExpensesUS$674.34m
Earnings-US$716.22m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-8.16
Gross Margin-4.78%
Net Profit Margin-81.76%
Debt/Equity Ratio358.1%

How did SRPT perform over the long term?

See historical performance and comparison